Fused tricyclic heterocyclic compounds useful for treating HIV infection

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

the group -A-B— is selected from —O—C(R 13 ) 2 —, —O—C(R 13 ) 2 —C(R 13 ) 2 —, —C(R 13 ) 2 —O—, —N(R 14 )—C(R 13 ) 2 —, —N(R 14 )—C(R 13 ) 2 —C(R 13 ) 2 — and —C(R 13 ) 2 —N(R 14 )—;

X is selected from a single bond, 5 or 6-membered monocyclic heteroaryl and —N(R 6 )C(O)—;

Y is a single bond or C 1 -C 3 alkylene;

R 1 is selected from C 6 -C 10 aryl, 5 or 6-membered monocyclic heteroaryl and 9 or 10-membered bicyclic heteroaryl, wherein said C 6 -C 10 aryl group, said 5 or 6-membered monocyclic heteroaryl group and said 9 or 10-membered bicyclic heteroaryl group can each be optionally substituted with up to three R 8 groups;

R 2 is selected from H, C 1 -C 6 alkyl, —(C 1 -C 6 alkylene) m —Z—R 16 , —N(R 25 ) 2 , —N(R 11 ) 2 and —OR 7 ;

R 3 is selected from H, C 1 -C 6 alkyl, —(C 1 -C 6 alkylene) m —Z—R 16 , —N(R 25 ) 2 , —N(R 11 ) 2 and —OR 7 ;

R 4 is selected from H, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 2 -C 6 alkenyl, —(C 1 -C 6 alkylene)—O—(C 1 -C 6 alkyl), —(C 1 -C 6 alkylene) m —Z—R 16 , —N(R 25 ) 2 , —N(R 11 ) 2 and —OR 7 , or R 4 and R 5 and the common carbon atom to which they are attached, join to form an exocyclic olefin group having the formula:

R 5 is selected from H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, —(C 1 -C 6 alkylene)—O—(C 1 -C 6 alkyl), —N(R 11 ) 2 and —OR 7 ;

each occurrence of R 6 is independently selected from H, C 1 -C 6 alkyl, —(C 1 -C 6 alkylene) m —Z—R 16 and —N(R 25 ) 2 ;

each occurrence of R 7 is independently selected from H, C 1 -C 6 alkyl, —(C 1 -C 6 alkylene)—O—(C 1 -C 6 alkyl) and C 3 -C 7 cycloalkyl;

each occurrence of R 8 is independently selected from C 1 -C 6 alkyl, halo, —OR 15 , —SR 15 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 15 ) 2 , R 16 , —C(O)OR 7 , —C(O)N(R 7 ) 2 and —NHC(O)R 7 ;

R 9 is selected from H, C 1 -C 6 alkyl, —(C 1 -C 6 alkylene)—O—C 1 -C 6 alkyl, —(C 1 -C 6 alkylene)—N(R 15 )—C 1 -C 6 alkyl, —C 1 -C 6 haloalkyl, —C 1 -C 6 hydroxyalkyl;

each occurence of R 10 is independently selected from H and C 1 -C 6 alkyl;

each occurrence of R 11 is independently selected from H, C 1 -C 6 alkyl, —S(O) 2 R 12 and —C(O)R 12 ;

each occurrence of R 12 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, 4 to 7-membered monocyclic heterocycloalkyl, 8 to 11-membered bicyclic heterocycloalkyl, 5 or 6-membered monocyclic heteroaryl and 9 or 10-membered bicyclic heteroaryl, wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 4 to 7-membered monocyclic heterocycloalkyl, said 8 to 11-membered bicyclic heterocycloalkyl group, said 5 or 6-membered monocyclic heteroaryl group and said 9 or 10-membered bicyclic heteroaryl group can each be optionally substituted with up to three R 8 groups;

each occurrence of R 13 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, halo, C 1 -C 6 haloalkyl, —(C 1 -C 6 alkylene) m —Z—R 16 , —N(R 25 ) 2 , —C(O)R 15 , —C(O)N(R 15 ) 2 and —NHC(O)R 15 ;

each occurrence of R 14 is independently selected from H, C 1 -C 6 alkyl, —(C 1 -C 6 alkylene) m —Z—R 16 , C 3 -C 7 cycloalkyl and C 6 -C 10 aryl, wherein said C 3 -C 7 cycloalkyl group and said C 6 -C 10 aryl group can be optionally substituted with one or more groups, each independently selected from C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, halo, C 1 -C 6 haloalkyl, —C(O)R 15 , —C(O)OR 15 , —C(O)N(R 15 ) 2 , —NHC(O)R 15 and —S(O) 2 R 15 ;

each occurrence of R 15 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl and benzyl; and

each occurrence of R 16 is independently selected from —P(O)(—OR 24 ) 2 ,

each occurrence of R 17 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl and benzyl, wherein said C 1 -C 6 alkyl can be optionally substituted with a group selected from halo, —OR 21 , —SR 21 , guanidino, —N(R 21 ) 2 , —C(O)OR 21 , —C(O)N(R 21 ) 2 , —NHC(O)R 21 , 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group can be optionally substituted with up to 2 groups, each independently selected from C 1 -C 6 alkyl, halo and —OR 26 ;

each occurrence of R 18 is independently selected from H, C 1 -C 6 alkyl, C 3 -C 7 cycloalkyl, phenyl and benzyl, wherein said C 1 -C 6 alkyl can be optionally substituted with a group selected from halo, —OR 21 , —SR 21 , guanidino, —N(R 21 ) 2 , —C(O)OR 21 , —C(O)N(R 21 ) 2 , —NHC(O)R 21 , 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, and wherein said phenyl group and said benzyl group can be optionally substituted with up to 2 groups, each independently selected from C 1 -C 6 alkyl, halo and —OR 21 ;

each occurrence of R 19 is independently selected from H, C 1 -C 20 alkyl, C 2 -C 20 alkenyl, —(C 1 -C 3 alkylene) m —(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m —(C 6 -C 10 aryl) and —(C 1 -C 3 alkylene) m -adamantyl, wherein said C 1 -C 20 alkyl group, said C 2 -C 20 alkenyl group, said C 6 -C 10 aryl group and said adamantyl group can be optionally substituted with up to three groups, each independently selected from halo, —OR 21 , —C(O)OR 21 , —CN, —NO 2 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 3 -C 7 cycloalkyl, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl, 9- or 10-membered bicyclic heteroaryl, —N(R 21 ) 2 , —C(O)N(R 21 ) 2 , —SR 21 , —S(O)R 21 , —S(O) 2 R 21 , —S(O) 2 N(R 21 ) 2 , —NHC(O)R 21 , —NHC(O)OR 21 and —NHC(O)N(R 21 ) 2 ;

each occurrence of R 20 is independently selected from H, C 6 -C 10 aryl, 5- or 6-membered monocyclic heteroaryl and 9- or 10-membered bicyclic heteroaryl, wherein said C 6 -C 10 aryl group, said 5- or 6-membered monocyclic heteroaryl group and said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five R 22 groups;

each occurrence of R 21 is independently H, C 1 -C 10 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —(C 1 -C 3 alkylene) m —(C 3 -C 7 cycloalkyl), —(C 1 -C 3 alkylene) m —(C 6 -C 10 aryl), —(C 1 -C 3 alkylene) m —(4 to 7-membered heterocycloalkyl), —(C 1 -C 3 alkylene) m -(5- or 6-membered monocyclic heteroaryl) or —(C 1 -C 3 alkylene) m -(9- or 10-membered bicyclic heteroaryl), wherein said C 3 -C 7 cycloalkyl group, said C 6 -C 10 aryl group, said 4 to 7-membered heterocycloalkyl group, said -5- or 6-membered monocyclic heteroaryl group or said 9- or 10-membered bicyclic heteroaryl group can be optionally substituted with up to five R 22 groups;

each occurrence of R 22 is independently selected from C 1 -C 6 alkyl, halo, —OR 21 , —SR 21 , C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, —O—(C 1 -C 6 haloalkyl), —CN, —NO 2 , —N(R 21 ) 2 , —C(O)OR 21 , —C(O)N(R 21 ) 2 and —NHC(O)R 21 , or any two R 22 groups on adjacent ring carbon atoms can combine to form —O—R 23 —O—;

R 23 is —[C(R 10 ) 2 ] n —;

each occurence of R 24 is independently selected from H, C 1 -C 6 alkyl, C 6 -C 10 aryl, —(C 1 -C 6 alkylene)—O—(C 1 -C 20 alkyl), —(C 1 -C 6 alkylene)—O—C(O)—R 21 , and —(C 1 -C 6 alkylene)—O—C(O)O—R 21 ;

each occurence of R 25 is independently selected from H, C 1 -C 6 alkyl and —(C 1 -C 6 alkylene)—Z—R 16 ;

each occurrence of Z is independently —O—or a bond;

each occurrence of m is independently 0, 1 or 2; and

n is 1 or 2.

2. The compound of claim 1 , wherein X is —NHC(O)—, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein X is 5 or 6-membered monocyclic heteroaryl, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 , wherein X is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein Y is CH 2 , or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 having the formula:

or a pharmaceutically acceptable salt thereof,

wherein:

the group -A-B—is selected from —CH 2 —N(CH 3 )—, —O—CH 2 —, —O—CH 2 —CH 2 —and —CH 2 —O—,

R 1 is phenyl, which is substituted by up to three R 8 groups,

R 4 is selected from C 1 -C 6 alkyl and —(C 1 -C 6 alkylene)—O—(C 1 -C 6 alkyl); and

R 5 is C 1 -C 6 alkyl.

7. The compound of claim 1 , wherein R 1 is phenyl, which is substituted by 1 to 3 halo groups, which can be the same or different, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7 , wherein R 1 is 2,4-difluorophenyl, 3-chloro-2,4-difluorophenyl or 3-chloro-2-fluorophenyl, or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein the group -A-B— is —CH 2 —O—, or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein R 4 is —(C 1 -C 6 alkylene)—O—(C 1 -C 6 alkyl) , or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein R 4 is C 1 -C 6 alkyl, or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein R 5 is C 1 -C 6 alkyl, or a pharmaceutically acceptable salt thereof.

13. The compound of claim 12 , wherein R 5 is methyl, or a pharmaceutically acceptable salt thereof.

14. A compound selected from

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A method for the inhibition of HIV integrase in a subject in need thereof which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

17. A method for the treatment of infection by HIV or for the treatment or delay in the onset or progression of AIDS in a subject in need thereof, which comprises administering to the subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition of claim 15 , further comprising one or more additional therapeutic agents selected from, lamivudine, abacavir, ritonavir, darunavir, atazanavir, emtricitabine, tenofovir, rilpivirine and lopinavir.

19. The method of claim 16 , further comprising administering to the subject one or more additional therapeutic agents selected from, abacavir, lamivudine, ritonavir and lopinavir, wherein the amounts administered of the compounds are together effective to treat infection by HIV or to treat or delay the onset or progression of AIDS.